Stocktoria
Voyager Therapeutics, Inc. VYGR
Voyager Therapeutics, Inc. (VYGR) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $40.4M at a -296.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.698 |
| Retained earnings / assets | -1.767 |
| EBIT / assets | -0.523 |
| Equity / liabilities | 3.489 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
FAQ
Is VYGR financially healthy?
Voyager Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VYGR pay a dividend?
No, Voyager Therapeutics, Inc. does not currently pay a dividend.
How profitable is VYGR?
In FY2025, Voyager Therapeutics, Inc. had a net margin of -296.5% and a return on equity of -61.1%.
What is the analyst price target for VYGR?
The average Wall-Street price target for Voyager Therapeutics, Inc. is $14.89, about 365.3% above the recent price, from 9 analysts (consensus: strong buy).
Is VYGR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Voyager Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.